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Covid-19  laboratory
preparedness  in  Africa:
lessons can be learned from
the Ebola outbreak, write Dr.
Ann H. Kelly, Eva Vernooij,
and Dr. Alice Street
As  Covid-19  pandemic  expands  its  global  reach,  increasing
testing capacity has taken centre stage in government and
international  agendas.  Drawing  on  research  and  policy
engagement  in  Sierra  Leone,  the  DiaDev  (Investigating
Diagnostic Devices in Global Health) team at the University of
Edinburgh  show  the  critical  importance  of  investing  in
laboratory capacity. New diagnostic devices are only effective
insofar as they can be integrated into the broader health
system  and  supported  by  continuous  supply  chains,  trained
medical staff and closely aligned information systems.
“We  have  a  simple  message  for  all  countries”  declared  Dr
Tedros  Adhanom  Ghebreyesus,  Director-General  of  the  World
Health Organization. “Test, test, test.”  Accurate diagnosis
is essential to mitigate the increasingly disastrous impact of
the COVID-19 outbreak. Without knowing who among the general
population is sick or has previously been infected, policy
makers are flying blind, facing unpredictable surges in cases,
health  workforce  shortages  and  an  interminable  cycle  of
lockdowns and forced closures.
But while the economic and public health rationale of mass
testing  is  irrefutable,  if  the  past  two  months  of  this
pandemic has taught us anything, it is that following Tedros’
mandate is hardly straightforward. Rapidly developing tests
from  scratch  and  deploying  them  widely  demands  clinical,
commercial  and  regulatory  coordination  and,  above  all,  a
sufficiently-prepared and well-integrated laboratory system.
As the outbreak moves into the African continent, the question
of  diagnostic  capacity  looms  large.  A  position  piece,
published  last  week  in  the  African  Journal  of  Laboratory
Medicine,  offers  a  key  perspective  on  what  is  needed  for
robust diagnostic response in an outbreak and the role tests
can play in building resilient health systems. Co-authored by
the  DiaDev  team  at  the  University  of  Edinburgh  and  Kings
College  London  and  policy-makers,  doctors,  public  health
experts, laboratory scientists from Sierra Leone, the paper
reflects on efforts to scale up diagnosis during the Ebola
outbreak, the longer-term impact of those investments on the
health system and provides some key lessons for the COVID-19
response in Africa and more widely.
 
Diagnostic tests need diagnostic systems
At the root of the 2014–2016 Ebola Outbreak was an inability
to  quickly  diagnose  and  isolate  cases.  With  unprecedented
speed, a range of novel Ebola diagnostic tools, from automated
PCR machines designed for laboratory benchtops to rapid test
kits that could be used at the point of care, were trialled in
Sierra Leone, helping to bring the outbreak to an end. But
while important, increasing the availability of tests was only
a first step. To safely transport samples, source reagents,
dispose of hazardous materials, and correctly interpret and
feed-back  diagnostic  data  into  clinical  and  public  health
decision-making necessitated health system-wide support.
The extent to which laboratory strengthening efforts during
the Ebola outbreak have prepared West African countries for
Covid-19 remains uncertain. One important legacy in Sierra
Leone  is  a  national  cohort  of  laboratory  workers  with
experience of PCR testing. A number of GeneXpert PCR machines,
which can be repurposed for SARS-COV-2 testing, also remain in
country. But prioritisation during the outbreak of disease-
specific Ebola tests, to the detriment of broader laboratory
strengthening  efforts,  means  weak  supply  chains  and  waste
management systems remain major points of vulnerability across
the region.
 
National experts and institutions need to be fully engaged
When  it  comes  to  the  ready  deployment  of  global  health
innovations in Africa, regulatory capacity is often neglected.
In an effort to accelerate R&D for Ebola diagnostics, the
World  Health  Organization  developed  the  WHO  Emergency  Use
Listing (EUL) to expedite the evaluation of new tools in the
epidemic.  While  ostensibly  the  aim  was  to  alleviate  the
regulatory  burden  on  National  Regulatory  Agencies  (NRAs),
without local input or support, national agencies struggled to
register the influx of new tests. Regulatory authorities can
be advocates for new medical products, but need manpower and
expertise to evaluate device performance, guide deployment and
procurement and to provide the quality assurance and post-
market surveillance essential for safeguarding patients and
health staff. The leadership of the Africa CDC in coordinating
diagnostic capacity in response to the Covid-19 outbreak has
meant national experts are more likely to be heard. A modified
EUL procedure launched for COVID-19 places increased emphasis
on  the  role  of  NRAs,  but  for  regulatory  alignment  to  be




Africa is the next frontier for the pandemic. At the time of
writing, the number of confirmed cases is near 10,000. What
epidemiological realities lie behind that number is unclear,
as diagnostic capacities across the continent differ widely.
Currently, there are more than 100 rapid point-of-care devices
for  Covid-19  in  the  pipeline,  and  the  global  health
organisation  FIND  is  assisting  African  governments  with
evaluating rapid tests for Covid-19 coming onto the market.
But the emphasis on novel tests, while important, distracts
from interventions that are just as critical for a successful
response while building capacity for the future.
The Sierra Leonean experience makes clear that investment in
new tests is just the starting point. If COVID-19 is going to
be contained, substantial investments must be made in national
laboratory networks and the supply chains, waste management
systems, and health information infrastructures that support
them. This is the key to building strong laboratory systems
for the next epidemic.
 
An earlier version of this piece was published on 9th April
2020 on the Kings College London Covid-19 website.
Images included in this essay feature laboratory workers and
cleaners working at health facilities in and around Freetown
and  were  taken  by  Olivia  Acland  for  the  DiaDev  research
project.
Research  for  this  article  was  undertaken  as  part  of  the
‘Investigating Diagnostic Devices in Global Health’ research
project  (www.diadev.eu)  and  was  supported  by  the  European
Research Council (ERC) under the European Union’s Horizon 2020
research and innovation programme grant agreement No 715450.
 
 
 
 
